Abemaciclib plus fulvestrant showed an increase in progression free survival in a study of 669 women with HR+, HER2− breast cancer that had progressed while receiving neoadjuvant or adjuvant endocrine therapy. The gene discussed is HR; the disease is breast carcinoma.